Biotech Startups

Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.

1 investor

Abionic develops the abioSCOPE, a near-patient rapid diagnostic platform that uses nanofluidic immunoassay technology to deliver lab-quality results from a single drop of blood within minutes. The platform is designed for clinical settings including hospitals and laboratories to enable early detection of conditions such as sepsis.

1 investor

Abliva develops treatments for primary mitochondrial disease, a rare orphan disease caused by impaired cellular energy metabolism in the mitochondria. The company focuses on pharmaceutical research and development to address an unmet medical need where no effective treatments currently exist.

1 investor

Abolis is a microbial biotechnology company that designs custom microorganisms to produce ingredients sustainably using metabolic engineering, fermentation, and machine learning. The company serves cosmetics, healthcare, nutrition, and specialty chemicals industries with tailored biosolutions for manufacturing.

1 investor

Abologix is a biopharmaceutical company developing two monoclonal antibodies that target JAM-C and Olfactomedin-like protein 3 (Olfml3) for oncology indications. It is a spin-out from the University of Geneva and Geneva University Hospitals.

1 investor

Arx is a self-hosted microbial genomics platform that enables researchers to store, organize, and analyze genomic data through interactive visualization and comparative analysis tools. The platform serves academic and research institutions studying microbial genomes.

1 investor

ABYRX develops synthetic, absorbable surgical biomaterials, including a bone hemostat used to stop bleeding on bone surfaces during surgery. Its products are tissue-free and designed to absorb after implantation for use in surgical and orthopedic procedures.

1 investor

Eagle Pharmaceuticals develops and commercializes specialty pharmaceutical products for acute care and oncology, including injectable medications for procedural sedation, chemotherapy, lymphomas, and malignant hyperthermia management.

1 investor

Acadia is a biopharmaceutical company developing therapies for underserved neurological disorders and rare diseases. The company operates across North America and Europe, leveraging expertise in areas including Parkinson's disease psychosis and Rett syndrome.

1 investor

Accelerated Biosciences commercializes human trophoblast stem cells (hTSC) and derived platforms for therapeutic development, serving pharmaceutical and biotech partners seeking accelerated pathways to clinical products. The company addresses aging and healthcare cost challenges through cell-based therapeutics.

1 investor

Accelerated Diagnostics is developing decentralised diagnostics for human and veterinary markets, with a product launch planned for July 2026.

1 investor

Access2Bone develops bone graft products containing human tissue-based compositions for orthopedic surgeries. The company's offerings are designed for foot, ankle, and spine fusion procedures.

1 investor

Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.

1 investor

ACEA Therapeutics is a clinical-stage pharmaceutical company developing small molecule inhibitors, antibody drug conjugates, and cell therapies to address unmet needs in cancer, autoimmune disease, and COVID-19. The company operates manufacturing and commercial capabilities in China and has multiple candidates in clinical development.

1 investor

Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.

1 investor

Achilles Therapeutics, a UK biotech company, is in members voluntary (solvent) liquidation as of March 2025, with joint liquidators appointed from Teneo Financial Advisory. The page is a liquidation notice for creditors and shareholders rather than an active company site.

1 investor

Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies. The company serves rare disease patients and their families globally.

1 investor

Acorn Genetics is developing technology to detect genetic and epigenetic markers rapidly and on-site, without sending samples to central labs. Its applications span disease marker detection and genomic monitoring for crop protection, ecosystems, and food security.

1 investor

Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.

1 investor

Biotech developing small-molecule therapies for respiratory, inflammatory and autoimmune diseases, acquired by Boehringer Ingelheim.

1 investor

Actio is a precision medicine company developing therapeutics by leveraging genetic insights to treat rare diseases and common conditions at their molecular root. The company focuses on identifying genes with dysregulated activity and designing therapies to restore normal gene function.

1 investor

Actipulse Neuroscience develops non-invasive brain stimulation technologies using high-frequency magnetic pulses to treat central nervous system disorders, including major depressive disorder and neurodegenerative diseases. The company conducts clinical research on transcranial neuromodulation devices.

1 investor

Activ'Inside develops proprietary food supplement active ingredients for neuronutrition and nutricosmetics applications, supported by scientific research and clinical studies. The company supplies branded ingredients and botanical extracts to manufacturers formulating nutraceutical products.

1 investor

ActNova develops "ActVerse", a web-based software that analyzes videos of animal experiments to automatically and accurately assess animal behavior. It targets pharmaceutical companies, hospitals, and university research labs conducting preclinical animal testing, aiming to reduce the number of animals sacrificed in research.

1 investor